Latest News - AbbVie
Top Corporates Hub
AbbVie
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
05.05.2026 12:05
AbbVie (NYSE: ABBV) today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago. AbbVie will present 18 abstracts, including real-world evidence and long-term findings for SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) in Crohn's disease and ulcerative colitis.
Guggenheim Reiterates Buy on AbbVie, Maintains $249 Price Target
01.05.2026 11:44
Guggenheim analyst Vamil Divan reiterates AbbVie (NYSE:ABBV) with a Buy and maintains $249 price target.
Is AbbVie Inc. (ABBV) One of the Best Drug Stocks to Buy According to Analysts?
01.05.2026 07:57
AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy according to analysts. AbbVie Inc. (NYSE:ABBV) announced on April 27 the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active Crohn’s disease. Management […]
Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month
30.04.2026 13:00
Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, today announced a charitable initiative in recognition of Skin Cancer Awareness Month. Throughout May, the company will donate $10 to The Skin Cancer Foundation for every new person who joins Allē through its "Refer a Friend" program, up to a total contribution of $100,000. New members who join through a referral will also receive $50 off their first Allergan Aesthetics treatment and the referring member will receive $10 off their next treatme
AbbVie Q1 Earnings Call Highlights
30.04.2026 02:41
AbbVie (NYSE:ABBV) reported first-quarter 2026 results that exceeded its expectations and prompted an increase to full-year guidance, with management citing broad-based momentum across the company’s commercial portfolio and multiple pipeline and business development updates. Quarterly results and r
AbbVie Inc (NYSE:ABBV) Beats Q1 Estimates and Raises Full-Year Profit Guidance
29.04.2026 12:27
AbbVie reported strong Q1 2026 results, beating EPS estimates and raising its full-year profit forecast. Growth drivers offset Humira's decline, though shares saw only a modest pre-market gain after recent weakness.
AbbVie Reports First-Quarter 2026 Financial Results
29.04.2026 11:47
AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2026.
AbbVie Raises Fiscal Year Guidance on Immunology, Neuroscience Growth
29.04.2026 08:39
By Nicholas G. Miller AbbVie raised its full-year adjusted earnings guidance and reported higher first-quarter revenue, boosted by growth in its immunology and neuroscience portfolios. ...
AbbVie : ABBV 1Q26 Press Release Final
29.04.2026 08:14
PRESS RELEASE AbbVie Reports First-Quarter 2026 Financial Results Reports First-Quarter Diluted EPS of $0.39 on a GAAP Basis, a Decrease of...
AbbVie: Q1 Earnings Snapshot
29.04.2026 08:03
NORTH CHICAGO, Ill. — NORTH CHICAGO, Ill. — AbbVie Inc. on Wednesday reported first-quarter earnings of $695 million. The North Chicago, Illinois-based company said it had net income of 39...
Assessing AbbVie (ABBV) Valuation After Recent Share Price Softness And Long Term Gains
29.04.2026 03:09
What AbbVie’s recent share performance tells you AbbVie (ABBV) has been drawing attention after recent share performance that contrasts shorter term weakness with longer term gains, prompting investors to reassess how its current valuation lines up with underlying fundamentals. See our latest analysis for AbbVie. Recent trading has been soft, with a 30 day share price return of 5.59% and a year to date share price return of a 13.79% decline, even as the 5 year total shareholder return of...
AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease
27.04.2026 12:05
AbbVie (NYSE: ABBV) today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® (risankizumab-rzaa) for subcutaneous (SC) induction for the treatment of adult patients with moderately to severely active Crohn's disease (CD).
Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy
27.04.2026 12:00
ALAMEDA, Calif., April 27, 2026--Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy
How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise
27.04.2026 11:00
Nearly two-thirds of patients who received Oruka Therapeutics' experimental psoriasis treatment had completely clear skin after 16 weeks.
AbbVie Inc. (ABBV) Receives CRL from the FDA About the Biologics License Application for trenibotulinumtoxinE
27.04.2026 05:28
AbbVie Inc. (NYSE:ABBV) is one of the best low volatility stocks to invest in right now. AbbVie Inc. (NYSE:ABBV) announced on April 23 that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration regarding the Biologics License Application for trenibotulinumtoxinE, which is a first-in-class botulinum neurotoxin serotype E with a rapid […]
AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug
25.04.2026 15:01
AbbVie Inc. shares are down during Friday’s premarket session following a Complete Response Letter (CRL) from the FDA regarding the Biologics License Application for trenibotulinumtoxinE (TrenibotE). The letter requested additional information about manufacturing processes but did not raise any safety or efficacy concerns. FDA Rejection Hits AbbVie Wrinkle Drug Filing The FDA’s CRL does not require additional clinical studies, and AbbVie is confident in addressing the agency’s feedback promptly.
LSI Industries And 2 Other Stocks That May Be Priced Below Estimated Value
24.04.2026 11:38
The United States market has remained flat over the past week but has seen a significant increase of 30% over the past year, with earnings projected to grow by 16% annually in the coming years. In this context, identifying stocks that may be undervalued can provide opportunities for investors seeking to capitalize on potential growth at a reasonable price.
15 Press Releases You Need to See This Week
24.04.2026 10:02
With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.
10 Dividend Growth Stocks: April 2025
24.04.2026 09:00
Ranked top 10 dividend growth stocks with 3.3%+ yields using a new 9-factor, 10-point quality scoring systemâfind todayâs best picks now.
AbbVie Provides Update on TrenibotulinumtoxinE Biologics License Application in the U.S.
24.04.2026 04:49
NORTH CHICAGO - AbbVie today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding the Biologics License Application for trenibotulinumtoxinE ,...